Plus Therapeutics Expands ReSPECT™ Clinical Trial to MD Anderson Cancer Center
December 01 2020 - 7:30AM
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a
clinical-stage pharmaceutical company developing novel, targeted
and personalized therapies for rare and difficult to treat cancers,
today announced that the University of Texas MD Anderson Cancer
Center is now an active clinical trial site in its ongoing ReSPECT™
Phase 1 clinical trial, currently supported by the National Cancer
Institute (NCI). ReSPECT is a multi-center, dose-finding study
evaluating the Company’s lead investigational asset, Rhenium
NanoLiposome (RNL™), in patients with recurrent glioblastoma (GBM).
The study will be conducted by MD Anderson’s
Department of Neurosurgery with Jeffrey Weinberg, M.D., Professor
of Neurosurgery and the Deputy Chair and Vice-Chair of Clinical
Operations in The Department of Neurosurgery, as primary
investigator.
“We are very excited to now have the MD Anderson
Cancer Center enrolling patients in the ReSPECT clinical trial,”
said Andrew J. Brenner, M.D., Ph.D., Associate Professor of
Medicine, Neurology, and Neurosurgery at The University of Texas,
Health Services Center at San Antonio and principle investigator of
the ReSPECT trial. “Jeffrey and his team are a valuable addition to
our efforts to advance RNL as a potential new treatment option for
recurrent GBM.”
“We are pleased to add Dr Weinberg and the MD
Anderson Cancer Center team to our growing list of ReSPECT trial
sites,” said Marc Hedrick, M.D., President and Chief Executive
Officer of Plus Therapeutics. “The company will significantly
benefit from the exceptional team of institutions as well as
clinical and scientific advisors with whom we are working that all
share our dedication to improving the care of GBM patients.”
As the Company previously disclosed, the sixth
dose escalation cohort of the ReSPECT trial is underway and
expected to enroll by the end of 2020. In September 2020, the U.S.
Food and Drug Administration granted both Orphan Drug designation
and Fast Track designation to RNL for the treatment of patients
with glioblastoma. Additional details about the ReSPECT trial are
available at clinicaltrials.gov (NCT01906385).
About Plus Therapeutics, Inc.
Plus Therapeutics (Nasdaq: PSTV) is a
clinical-stage pharmaceutical company whose radiotherapeutic
portfolio is concentrated on nanoliposome-encapsulated
radionuclides for several cancer targets. Central to the Company’s
drug development is a unique nanotechnology platform designed to
reformulate, deliver and commercialize multiple drugs targeting
rare cancers and other diseases. The platform is designed to
facilitate new delivery approaches and/or formulations of safe and
effective, injectable drugs, potentially enhancing the safety,
efficacy and convenience for patients and healthcare providers.
More information may be found at PlusTherapeutics.com and
ReSPECT-Trials.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains certain statements
that may be deemed “forward-looking statements” within the meaning
of U.S. securities laws. All statements, other than statements of
historical fact, that address activities, events or developments
that we intend, expect, project, believe or anticipate and similar
expressions or future conditional verbs such as will, should,
would, could or may occur in the future are forward-looking
statements. Such statements are based upon certain assumptions and
assessments made by our management in light of their experience and
their perception of historical trends, current conditions, expected
future developments and other factors they believe to be
appropriate. These statements include, without limitation,
statements about: the Company’s potential to facilitate new
delivery approaches and/or formulations of safe and effective,
injectable drugs, potentially enhancing the safety, efficacy and
convenience for patients and healthcare providers; the Company’s
potential to develop drug candidates currently in its product
pipeline; and the Company’s potential to develop additional drugs
outside of its current pipeline. The forward-looking statements
included in this press release are subject to a number of
additional material risks and uncertainties, including but not
limited to: the risk that the Company is not able to successfully
develop product candidates that can leverage the U.S. FDA’s
accelerated regulatory pathways; and the risks described under the
heading “Risk Factors” in the Company’s Securities and Exchange
Commission filings, including in the Company’s annual and quarterly
reports. There may be events in the future that the Company is
unable to predict, or over which it has no control, and its
business, financial condition, results of operations and prospects
may change in the future. The Company assumes no responsibility to
update or revise any forward-looking statements to reflect events,
trends or circumstances after the date they are made unless the
Company has an obligation under U.S. federal securities laws to do
so.
Investor ContactPeter Vozzo Westwicke/ICR(443) 377-4767
Peter.Vozzo@westwicke.com
Media ContactTerri ClevengerWestwicke/ICR(203)
856-4326Terri.Clevenger@westwicke.com
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From Sep 2023 to Sep 2024